MT-1 expression was statistically significant in breast cancers negative for HER2-, estrogen- and progesterone-receptors in comparison to tumors that were positive for these hormone receptors (p < 0.05), (Table 3). The gene discussed is ERBB2; the disease is breast carcinoma.